Cardiff Oncology, Inc. (CRDF) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cardiff Oncology, Inc. (CRDF) Healthcare & Pipeline Overview

Cardiff Oncology, Inc. is a clinical-stage biotechnology company specializing in the development of cancer therapeutics, with a focus on its lead drug candidate, onvansertib, an oral selective Polo-like Kinase 1 Inhibitor. The company targets unmet needs in cancer treatment, positioning itself within the competitive oncology market.

What Is the Investment Thesis for CRDF?

Cardiff Oncology presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of onvansertib, their lead drug candidate. Positive clinical trial results could significantly increase the company's valuation. However, the company's negative profit margin of -7732.2% and gross margin of -1890.4% highlight its reliance on future funding or partnerships. Successful progression of CY140 and TROV-053 through clinical trials represents additional potential upside. Investors should closely monitor clinical trial data, regulatory milestones, and the company's cash runway.

Based on FMP financials and quantitative analysis

CRDF Key Highlights

• Market capitalization of $57.3M reflects the company's current valuation in the biotechnology sector.
• Negative profit margin of -7732.2% indicates that the company is currently operating at a loss, common for clinical-stage companies.
• Gross margin of -1890.4% suggests high costs associated with research and development activities.
• Beta of 1.42 indicates that the stock is more volatile than the market average.
• No dividend is currently offered, which is typical for growth-oriented biotechnology companies focused on reinvesting earnings into research and development.

Who Are CRDF's Competitors?

CRDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRDF's Key Strengths?

• Novel drug candidates targeting validated oncology targets.
• Experienced management team with expertise in drug development.
• Strong intellectual property protection.
• Focus on unmet medical needs in cancer treatment.

What Are CRDF's Weaknesses?

• Clinical-stage company with no currently approved products.
• High cash burn rate and reliance on future funding.
• Limited commercialization capabilities.
• Concentration of pipeline on a few key drug candidates.

What Could Drive CRDF Stock Higher?

• Release of Phase 2 clinical trial data for onvansertib in metastatic colorectal cancer (2027).
• Initiation of Phase 3 clinical trial for onvansertib in KRAS-mutated non-small cell lung cancer (2027).
• Enrollment and progression of patients in ongoing clinical trials for CY140 and TROV-053.
• Potential for strategic partnerships or collaborations with larger pharmaceutical companies.

What Are the Key Risks for CRDF?

• Financial-distress signal — its Altman Z-Score of -12.29 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-95.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Regulatory delays or rejection of drug candidates.
• Competition from other cancer therapies.
• High cash burn rate and need for additional funding.
• Dependence on the success of a limited number of drug candidates.

What Are the Growth Opportunities for CRDF?

• Onvansertib Development: The primary growth opportunity lies in the continued development and potential commercialization of onvansertib. The drug targets Polo-like Kinase 1 (PLK1), a validated oncology target. Positive results from ongoing clinical trials in various cancer types could lead to regulatory approvals and subsequent market entry. The global oncology market is projected to reach $286.6 billion by 2030, providing a substantial market opportunity for successful cancer therapeutics. Timeline: 2027-2030, pending clinical trial outcomes and regulatory approvals.
• CY140 Advancement: Advancing CY140, an inhibitor of PLK1, PLK2, and PLK3, through Phase 1/2 studies for solid tumors and leukemias represents another growth avenue. Successful clinical development could expand Cardiff Oncology's pipeline and address a broader range of cancer indications. The market for leukemia therapeutics is expected to reach $16.5 billion by 2028. Timeline: 2028-2032, dependent on clinical trial progress.
• TROV-054 Clinical Trials: The ongoing Phase 1b/2 study of TROV-054 in combination with FOLFIRI and bevacizumab for metastatic colorectal cancer presents a growth opportunity. Positive clinical data could lead to the development of a novel treatment regimen for this indication. The global colorectal cancer therapeutics market is projected to reach $14.8 billion by 2027. Timeline: 2027-2030, contingent on clinical trial results.
• TROV-053 Development: The Phase II clinical trial of TROV-053 in combination with Zytiga for metastatic castration-resistant prostate cancer offers a growth opportunity. Success in this trial could lead to a new therapeutic option for prostate cancer patients. The prostate cancer therapeutics market is expected to reach $12.1 billion by 2028. Timeline: 2027-2029, contingent on clinical trial outcomes.
• Strategic Partnerships: Cardiff Oncology can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations can provide access to funding, expertise, and established distribution networks. The biotechnology industry is characterized by frequent partnerships and acquisitions, offering potential for value creation. Timeline: Ongoing.

What Opportunities Does CRDF Have?

• Positive clinical trial results leading to regulatory approvals.
• Strategic partnerships with larger pharmaceutical companies.
• Expansion of pipeline through new drug discovery and development.
• Acquisition by a larger pharmaceutical company.

What Threats Does CRDF Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from other cancer therapies.
• Patent expirations.

What Are CRDF's Competitive Advantages?

• Intellectual property protection through patents on drug candidates.
• Proprietary knowledge and expertise in PLK1 inhibition.
• Clinical trial data demonstrating the efficacy and safety of drug candidates.
• Established relationships with pharmaceutical manufacturers.

What Does CRDF Do?

Cardiff Oncology, Inc., established in 1999 and headquartered in San Diego, California, is a clinical-stage oncology company dedicated to developing innovative medicine treatments for cancer patients. Originally incorporated as Trovagene, Inc., the company rebranded as Cardiff Oncology in May 2012, signaling a strategic shift towards oncology-focused drug development. The company's primary focus is onvansertib, an oral selective Polo-like Kinase 1 (PLK1) inhibitor, designed to target various cancers. In addition to onvansertib, Cardiff Oncology is developing CY140, an inhibitor of PLK1, PLK2, and PLK3, currently in Phase 1/2 studies for solid tumors and leukemias. The company is also conducting clinical trials for metastatic colorectal cancer and evaluating TROV-054 in a Phase 1b/2 study in combination with FOLFIRI and bevacizumab. Furthermore, TROV-053 is undergoing Phase II clinical trials in combination with Zytiga for metastatic castration-resistant prostate cancer. Cardiff Oncology primarily serves pharmaceutical manufacturers, aiming to partner and commercialize its therapeutic candidates. The company's pipeline reflects a commitment to addressing unmet medical needs in oncology through targeted therapies.

What Products and Services Does CRDF Offer?

• Develops medicine treatments for cancer patients.
• Focuses on oral selective Polo-like Kinase 1 (PLK1) Inhibitors for anti-cancer therapeutics.
• Conducts clinical trials for various cancer types, including metastatic colorectal cancer and prostate cancer.
• Develops inhibitors of PLK1, PLK2, and PLK3 for solid tumors and leukemias.
• Partners with pharmaceutical manufacturers for drug development and commercialization.
• Researches and develops novel cancer therapies to address unmet medical needs.

How Does CRDF Make Money?

• Develops and patents novel cancer therapeutics.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of drug candidates.
• Seeks regulatory approval from agencies like the FDA.
• Partners with pharmaceutical companies for commercialization and distribution.

What Industry Does CRDF Operate In?

Cardiff Oncology operates within the highly competitive biotechnology industry, specifically targeting the oncology market. The oncology market is characterized by significant unmet medical needs and substantial growth opportunities, driven by an aging population and advancements in cancer diagnostics and treatment. The company competes with both large pharmaceutical companies and smaller biotechnology firms developing novel cancer therapies. Success in this industry requires significant investment in research and development, navigating complex regulatory pathways, and securing strategic partnerships for commercialization. The biotechnology industry is subject to rapid innovation and evolving treatment paradigms.

Who Are CRDF's Key Customers?

• Pharmaceutical manufacturers seeking novel cancer therapeutics.
• Oncology patients in need of new treatment options.
• Healthcare providers prescribing cancer therapies.
• Research institutions involved in cancer research.

Net buyingInsider Activity

Over the past six months, Cardiff Oncology, Inc. insiders filed 13 SEC Form 4 transactions — 0 sales and 13 purchases. On net that is roughly 2.4M shares acquired (about $3.9M) — insiders putting money in tends to read as conviction.

ROE -95%Key Financial Metrics

Return on equity for Cardiff Oncology, Inc. stands at -95.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -91.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -42.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -50.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Cardiff Oncology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.29 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cardiff Oncology, Inc. revenue of about $244K for fiscal 2026, with EPS near $-0.68. The estimate reflects 7 contributing analysts.

CRDF Valuation & Market Position

With a $57.3M market cap, Cardiff Oncology, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CRDF's quantitative score of 16/100 is below the peer average of 79/100.

CRDF Financials

CRDF Latest News

CRDF Analyst Consensus

CRDF MoonshotScore

Latest Cardiff Oncology, Inc. Analysis

What Investors Ask About Cardiff Oncology, Inc. (CRDF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources